Can you say "clinically proven" in Indian pharma promotional material?
Conditionally restricted. 'Clinically proven' is not prohibited in promotion to doctors in India. It may be used only if, at a minimum, three conditions hold. First, it must be consistent with the marketing approval (Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 1.2). Second, it must be balanced and verifiable, must not mislead, and must be capable of substantiation (Clause 1.3). Third, it must rest on an up-to-date evaluation of all available evidence (Clause 2.1).
In short
- Status: conditionally restricted.
- Governing instrument: Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clauses 1.2 and 1.3, and Section 2 (Claims & Comparisons), Clause 2.1. Also the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Sections 3(d) and 4. Section 14(c) of that Act saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. The Act's other savings in Section 14, and exemptions under Section 15, also apply. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 also apply to Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). The conditions say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team.
- UCPMP 2024 does not name this term.
- First checked by two independent AI models against the live web. Citations re-checked on 6 October 2026. They were checked against the official texts of the Code, the Drugs and Magic Remedies Act and the CDSCO 2016 consolidated text of the Drugs Rules.
Which instrument governs this
Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clauses 1.2 and 1.3, and Section 2 (Claims & Comparisons), Clause 2.1. Also the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Sections 3(d) and 4. Section 14(c) of that Act saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. The Act's other savings in Section 14, and exemptions under Section 15, also apply. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 also apply to Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). The conditions say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team.
UCPMP 2024 does not name this phrase. It is an evidential claim. It must be consistent with the marketing approval (Clause 1.2). The test is also whether the clinical evidence behind it exists, is up to date, and supports the claim as worded (Clauses 1.3 and 2.1).
What verification returned
'Clinically proven' is not prohibited in promotion to doctors in India. It may be used only if, at a minimum, three conditions hold. First, it must be consistent with the marketing approval (Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 1.2). Second, it must be balanced and verifiable, must not mislead, and must be capable of substantiation (Clause 1.3). Third, it must rest on an up-to-date evaluation of all available evidence (Clause 2.1). The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 also applies to an advertisement for a drug. Sections 3(d) and 4 of that Act are the relevant ones. The Act covers doctor-directed material too, but Section 14(c) saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. The Act's other savings in Section 14, and exemptions under Section 15, also apply. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 add a condition for Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). They say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team. Prefer the specific result, for example 'In [trial], [number] patients, [drug] reduced [endpoint] by [result] versus [comparator] at [time point]'.
How this was checked
Two independent AI models were asked the same question against the live web. They were Gemini 2.5 Pro with Google Search grounding, and OpenAI GPT-5 with web search. A third model then judged whether they agreed on the substance rather than the wording. Every source cited was fetched over HTTP to confirm it exists. A fetch confirms only that a source exists. It does not confirm that the source supports the statement. So on 6 October 2026 the citations on this page were re-checked. They were checked against the official texts of the Code, the Drugs and Magic Remedies Act and the CDSCO 2016 consolidated text of the Drugs Rules. They were corrected where they were wrong. Terms that did not reach agreement between the models are not published.
Sources checked
- UCPMP 2024 policy page, Department of Pharmaceuticals
- UCPMP 2024, copy on the UCPMP portal of the Department of Pharmaceuticals (PDF)
- UCPMP 2024 important documents page, Department of Pharmaceuticals
- Drugs and Magic Remedies Act 1954, consolidated text on thc.nic.in (PDF)
- Drugs and Cosmetics Act 1940 and Rules 1945, CDSCO consolidated text (PDF)
Frequently asked questions
Can you say "clinically proven" in pharma promotion in India?
Conditionally restricted. 'Clinically proven' is not prohibited in promotion to doctors in India. It may be used only if, at a minimum, three conditions hold. First, it must be consistent with the marketing approval (Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 1.2). Second, it must be balanced and verifiable, must not mislead, and must be capable of substantiation (Clause 1.3). Third, it must rest on an up-to-date evaluation of all available evidence (Clause 2.1).
Which law and code govern the use of 'clinically proven'?
Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clauses 1.2 and 1.3, and Section 2 (Claims & Comparisons), Clause 2.1. Also the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Sections 3(d) and 4. Section 14(c) of that Act saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. The Act's other savings in Section 14, and exemptions under Section 15, also apply. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 also apply to Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). The conditions say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team.
How reliable is this answer?
It was first checked on 10 September 2026 by two independent AI models, Gemini 2.5 Pro and GPT-5. Both worked against the live web, and their answers were adjudicated for agreement. Every cited source was fetched to confirm it exists. A fetch confirms only that a source exists. So on 6 October 2026 the citations were re-checked. They were checked against the official texts of the Code, the Drugs and Magic Remedies Act and the CDSCO 2016 consolidated text of the Drugs Rules. They were corrected where they were wrong. Terms that did not reach agreement are not published. The Code and the law change, so check against the source before relying on it.
Check it before MLR does
Collateral Advisor flags this term in the pages you upload, for your team to review in context.
Free trial, no card needed. MarketingSense is a pre-MLR advisory assistant. Your medical, legal and regulatory team still makes the final call.